Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MEIP - MEI Pharma, Inc.
Market Cap 47.64M P/E - EPS this Y -313.10% Ern Qtrly Grth -
Income 17.78M Forward P/E -1.05 EPS next Y 34.80% 50D Avg Chg -
Sales 65.3M PEG 5.10 EPS past 5Y - 200D Avg Chg 16.00%
Dividend N/A Price/Book 1.39 EPS next 5Y -0.10% 52W High Chg -38.00%
Recommedations 3.00 Quick Ratio 4.59 Shares Outstanding 6.66M 52W Low Chg 79.00%
Insider Own 1.31% ROA 20.04% Shares Float 4.93M Beta 0.73
Inst Own 41.08% ROE 61.68% Shares Shorted/Prior 16.28K/16.08K Price 7.15
Gross Margin 75.54% Profit Margin 27.23% Avg. Volume 58,862 Target Price 6.00
Oper. Margin 39.81% Earnings Date Nov 7 Volume 17,020 Change -3.90%
Healthcare | Biotechnology | United States
About MEI Pharma, Inc.

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma, Inc. News
11/12/24 MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
09/19/24 MEI Pharma Reports Fiscal Year End 2024 Cash Position
08/12/24 MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
07/22/24 MEI Pharma to Consider Strategic Alternatives
07/01/24 7 Undervalued Biotech Stocks to Buy for Big-Time Returns
05/09/24 MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
04/11/24 MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
04/11/24 MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
04/10/24 MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
03/26/24 MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
03/09/24 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
02/13/24 MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
02/13/24 MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
02/08/24 Is MEI Pharma (MEIP) Attractively Priced?
01/16/24 MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anson Funds Management LP 10% Owner 10% Owner Sep 22 Buy 6.8525 48,060 329,331 864,188 09/25/23
Funicular Funds, LP 10% Owner 10% Owner Sep 22 Buy 6.8525 32,040 219,554 460,840 09/25/23
Anson Funds Management LP 10% Owner 10% Owner Sep 20 Buy 6.24 153,600 958,464 816,128 09/22/23
Funicular Funds, LP 10% Owner 10% Owner Sep 20 Buy 6.24 102,400 638,976 428,800 09/22/23